Advertisement US PTO Grants Patent To iCAD Lesion Metric - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

US PTO Grants Patent To iCAD Lesion Metric

US PTO has granted patent to iCAD, a provider of advanced image analysis and workflow solutions for the early identification of cancer, on Patent Number 7,660,448, which incorporates CAD lesion metrics to provide clinicians with enhanced clinical information.

The patent technology covers future iterations of the company’s SecondLook Digital Computer-Aided Detection (CAD) solution with potential application to the company’s other image analysis solutions.

Ken Ferry, President and CEO of iCAD, said: “Advancements covered by this new patent will incorporate CAD lesion metrics that can provide clinicians with insight into the system’s decision making process.”

US Patent has also been granted to iCAD’s Computed Tomography (CT) image analysis software, which aims to improve the way CT image analysis solutions can assess data three-dimensionally.

The patents are included among the broad patent portfolio iCAD, which has 27 granted US patents and 15 US patent applications pending.